Search clinical trials for: [14C]-AZD9742

Total 2761 results

AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
Hoffmann-La Roche

Completed

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
Vivozon, Inc.

Completed

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Healthy Adult Male

United States
Rachel Lieberman

Terminated

Capsular Tension Rings in Intraocular Lens Rotation

Cataract | Ophthalmoplegia | Ophthalmologic Complication

United States
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Healthy Volunteer | Coronavirus Disease 2019 (COVID-19)

China
Ardelyx

Completed

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Healthy Volunteers

United Kingdom
Ardelyx
AstraZeneca

Completed

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

End Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5

United States
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
Ardelyx

Completed

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
Ardelyx

Completed

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Hyperphosphatemia

United States, Poland, United Kingdom, Slovakia
Ardelyx

Completed

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Hyperphosphatemia

United States
Ardelyx

Completed

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
AstraZeneca

Completed

AZD9773 Dose Escalation Study

Severe Sepsis

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Healthy Volunteer

United States
Laekna Limited

Completed

Human Mass Balance and Biotransformation Study of [14C]Afuresertib

Healthy Volunteer

China
Indivior Inc.

Completed

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Opioid Use Disorder

United States
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Healthy Participants

Netherlands
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Human AME Study for Omaveloxolone

Healthy Male Subjects

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Athira Pharma
Alturas Analytics, Inc.; Labcorp Drug Development Inc

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Healthy Volunteers

United States
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Healthy Participants

Healthy Participants

United Kingdom
Biogen
Denali Therapeutics Inc.

Completed

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Healthy Volunteers

United States
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
Ardelyx

Completed

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Healthy Volunteers Food Interaction Study

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Completed

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Healthy

United States
H. Lundbeck A/S

Completed

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

Healthy

Netherlands
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
Rivus Pharmaceuticals, Inc.

Recruiting

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Healthy

United States
Biogen

Not yet recruiting

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer
Denali Therapeutics Inc.

Recruiting

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Healthy Volunteers

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Impact Therapeutics, Inc.

Not yet recruiting

A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects

Solid Tumor
Guangdong Raynovent Biotech Co., Ltd

Completed

Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China

Pharmacokinetics

China
Xizang Haisco Pharmaceutical Co., Ltd

Active, not recruiting

Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.

Healthy

China
Shanghai Henlius Biotech

Completed

Mass Balance Study of [14C]HLX208 in China Healthy Subjects

Mass Balance Study in Healthy Subjects

China
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

Healthy

United States

3

Subscribe